Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: The results of the ACCEL-DOUBLE-2N3 study

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1194-1197

  Jeong, Y H ^a,b   Abadilla, K A ^b,c   Tantry, U S ^b   Park, Y ^a   Koh, J S ^a   Kwak, C H ^a   Hwang, J Y ^a   Gurbel, P A ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE HEART INFARCTION; ALLELE; ASIAN; CAUCASIAN; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EXON; GENE DOSAGE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LETTER; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; STANDARD; ADULT; AGED; BLOOD CLOTTING PARAMETERS; CHEMISTRY; COHORT ANALYSIS; FEMALE; GENETICS; HETEROZYGOTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP;

ADENOSINE DIPHOSPHATE; ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE; CYTOCHROME P-450 CYP2C19;

EID: 84883772557     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12200     Document Type: Letter

References (9)

1. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R, et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-33.
2. Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, Shuldiner AR. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther 2011; 89: 455-9.
3. Yin OQ, Tomlinson B, Chow AH, Waye MM, Chow MS. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 2004; 44: 582-9.
4. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, Nakano S, Higuchi S. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19 m1 in exon 5 and CYP2C19 m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647-53.
5. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011; 106: 211-8.
6. Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010; 66: 871-7.
7. Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011; 97: 1239-44.
8. Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998; 45: 27-9.
9. Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators. Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention: The GIFT (Genotype Information and Functional Testing) Study. J Am Coll Cardiol 2012; 59: 1928-37.